Novel biomarkers associated with thoracic aortic disease.
Biomarkers
Gender
Hereditary thoracic aortic diseases
Sex
Thoracic aortic diseases
Journal
International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
21
07
2022
revised:
18
01
2023
accepted:
06
02
2023
pubmed:
17
2
2023
medline:
22
3
2023
entrez:
16
2
2023
Statut:
ppublish
Résumé
Biomarkers might help to improve diagnosis, surveillance and risk stratification of thoracic aortic disease (TAD). We explored the association between a broad spectrum of cardiovascular biomarkers with clinical characteristics and thoracic aortic diameter in TAD patients. Venous blood-samples were obtained in 158 clinically stable TAD patients visiting our outpatient clinic (2017-2020). TAD was defined as a thoracic aortic diameter ≥ 40 mm, or genetic confirmation (hereditary TAD). The cardiovascular panel III of the Olink multiplex platform was used for batch analysis of 92 proteins. A comparison was made between biomarker levels in patients with and without previous aortic dissection and/or surgery, and with and without hereditary TAD. Linear regression analyses were applied to identify (relative, normalized) biomarker concentrations associated with the absolute thoracic aortic diameter (AD Median age of study patients was 61.0 (IQR 50.3-68.8) years, 37.3% females. Mean AD Among a broad range of biomarkers, MMP-3 and IGFBP-2 were associated with disease severity in TAD patients. The pathophysiological pathways uncovered by these biomarkers, and their potential clinical use warrants further research.
Sections du résumé
BACKGROUND
Biomarkers might help to improve diagnosis, surveillance and risk stratification of thoracic aortic disease (TAD). We explored the association between a broad spectrum of cardiovascular biomarkers with clinical characteristics and thoracic aortic diameter in TAD patients.
METHODS
Venous blood-samples were obtained in 158 clinically stable TAD patients visiting our outpatient clinic (2017-2020). TAD was defined as a thoracic aortic diameter ≥ 40 mm, or genetic confirmation (hereditary TAD). The cardiovascular panel III of the Olink multiplex platform was used for batch analysis of 92 proteins. A comparison was made between biomarker levels in patients with and without previous aortic dissection and/or surgery, and with and without hereditary TAD. Linear regression analyses were applied to identify (relative, normalized) biomarker concentrations associated with the absolute thoracic aortic diameter (AD
RESULTS
Median age of study patients was 61.0 (IQR 50.3-68.8) years, 37.3% females. Mean AD
CONCLUSIONS
Among a broad range of biomarkers, MMP-3 and IGFBP-2 were associated with disease severity in TAD patients. The pathophysiological pathways uncovered by these biomarkers, and their potential clinical use warrants further research.
Identifiants
pubmed: 36796491
pii: S0167-5273(23)00181-X
doi: 10.1016/j.ijcard.2023.02.006
pii:
doi:
Substances chimiques
Matrix Metalloproteinase 3
EC 3.4.24.17
Insulin-Like Growth Factor Binding Protein 2
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-122Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Authors Carlijn Thijssen, Silvy Dekker, Lidia Bons, Laurie Geenen, Arjen Gökalp, Johanna Takkenberg, Mostafa Mokhles, Jos Bekkers, Elke Bouwens, Eric Boersma, Roland van Kimmenade and Jolien Roos-Hesselink declare that they have no conflict of interest.